Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent siRNA & mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic lipid integral to advanced lipid nanoparticle (LNP) formulations for siRNA and mRNA delivery. It enables endosomal escape via pH-dependent charge switching, remains neutral at physiological pH to reduce systemic toxicity, and demonstrates approximately 1000-fold higher potency for hepatic gene silencing compared to its precursor, DLin-DMA (Rafiei et al., 2025). This lipid is a core component in clinically validated LNPs and supports machine learning-driven optimization in mRNA drug delivery (Dlin-MC3-DMA and the Future...). APExBIO supplies Dlin-MC3-DMA (SKU: A8791), supporting reproducible research and translational workflows (product page).

Biological Rationale

Efficient intracellular delivery of nucleic acids is a bottleneck in gene therapy. The liver is a primary target for systemic siRNA and mRNA therapies due to natural LNP tropism and clinical relevance in hepatic diseases (Rafiei et al., 2025). Dlin-MC3-DMA's structure enables selective charge acquisition under acidic endosomal conditions, promoting endosomal disruption while minimizing off-target toxicity. This property facilitates cytoplasmic release of RNA therapeutics, essential for gene silencing and protein expression (Pepbridge, 2023). LNPs formulated with Dlin-MC3-DMA are also explored for immunomodulation, cancer immunochemotherapy, and vaccine development.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is an ionizable amino lipid. At acidic pH (e.g., within endosomes), it gains positive charge, facilitating electrostatic interactions with anionic endosomal lipids. This disrupts the endosomal membrane, enabling endosomal escape of the encapsulated siRNA or mRNA (Rafiei et al., 2025). At physiological pH (~7.4), Dlin-MC3-DMA is neutral, reducing non-specific interactions and toxicity. Its structure: (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, supports high membrane affinity and solubility in ethanol (≥152.6 mg/mL), but it is insoluble in water and DMSO. Dlin-MC3-DMA is combined with DSPC (phosphatidylcholine), cholesterol, and PEG-DMG to form stable LNPs. These LNPs efficiently encapsulate and protect nucleic acids until delivery (MK2206, 2023).

Evidence & Benchmarks

• Dlin-MC3-DMA-based LNPs achieve hepatic Factor VII gene silencing with up to 1000-fold higher potency over DLin-DMA precursors (Rafiei et al., 2025).
• ED50 for transthyretin (TTR) gene silencing in mice is 0.005 mg/kg; in non-human primates, 0.03 mg/kg (Rafiei et al., 2025).
• Machine learning-optimized LNPs with Dlin-MC3-DMA achieve high mRNA transfection efficiency (weighted F1-score ≥0.8 for ML model prediction in BV-2 microglia; see Table 1) (Rafiei et al., 2025).
• Dlin-MC3-DMA LNPs can shift microglia toward anti-inflammatory phenotypes by delivering IL10 mRNA, as shown by reduced TNF-α levels in LPS-activated human iPSC-derived microglia (Rafiei et al., 2025, Fig. 4).
• Dlin-MC3-DMA is a core component in FDA-approved LNP formulations for siRNA and mRNA therapeutics (DMG-PEG2000, 2023).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is foundational for:

• Lipid nanoparticle siRNA delivery platforms targeting hepatic and extrahepatic tissues.
• mRNA drug delivery lipid vehicles, including vaccine and immunotherapy applications.
• Machine learning-guided LNP optimization for cell-type-specific delivery (Rafiei et al., 2025).
• Cancer immunochemotherapy, where immune modulation is desired (Dlin-MC3-DMA and the Future...).

Dlin-MC3-DMA is not suitable for:

• Direct aqueous formulations; it is insoluble in water and DMSO.
• Applications requiring persistent cationic charge at physiological pH (risk of systemic toxicity).
• Gene delivery in cell types or conditions with poor endosomal acidification.

Common Pitfalls or Misconceptions

• Misconception: Dlin-MC3-DMA is active at neutral pH. Fact: It is largely neutral at physiological pH and only ionizes in acidic endosomes.
• Pitfall: Attempting to dissolve Dlin-MC3-DMA directly in water or DMSO leads to precipitation.
• Misconception: Dlin-MC3-DMA alone forms stable LNPs. Fact: It requires co-formulation with helper lipids (DSPC, cholesterol, PEG-lipids).
• Pitfall: Storage at above -20°C reduces shelf life and potency due to hydrolytic degradation.
• Boundary: Not all cell types respond equally; efficacy may be reduced in cells with impaired endosomal acidification or excessive efflux activity.

Workflow Integration & Parameters

Dlin-MC3-DMA (A8791, APExBIO) is typically formulated by mixing with DSPC, cholesterol, and PEG-DMG in ethanol, then rapidly mixing with an aqueous buffer containing siRNA or mRNA. Ethanol is removed by dialysis or ultrafiltration. The final LNP product should be stored at 4°C (short term) or -20°C (long term). Recommended N/P ratio (amine:phosphate) typically ranges from 3:1 to 6:1, but optimal ratios are context-dependent (MK2206, 2023). Use freshly prepared solutions to prevent degradation. For gene silencing in mice, doses as low as 0.005 mg/kg have been validated. Machine learning tools can assist in predicting optimal LNP design parameters for specific cell types or disease states (Rafiei et al., 2025).

For a foundational overview of mechanistic principles, see Dlin-MC3-DMA: Ionizable Liposome for Potent siRNA & mRNA ... (this article updates with new benchmarks and ML insights). For troubleshooting and advanced workflows, refer to Optimizing Lipid Nanoparticle siRNA Delivery... (this article clarifies pitfalls and parameterization).

Conclusion & Outlook

Dlin-MC3-DMA is a cornerstone in the field of ionizable cationic liposome technology, enabling precise and potent delivery of siRNA and mRNA via lipid nanoparticles. Its pH-responsive mechanism ensures efficient endosomal escape and low systemic toxicity. Ongoing research leverages Dlin-MC3-DMA for targeted gene silencing, mRNA vaccine formulation, and immunomodulation, with machine learning accelerating rational LNP design. APExBIO continues to supply high-quality Dlin-MC3-DMA for translational and clinical research. Future advances will further increase tissue specificity, improve safety, and expand therapeutic applications.